Open Access
Med Sci (Paris)
Volume 34, Number 12, Décembre 2018
Page(s) 1025 - 1028
Section Le Magazine
Published online 09 January 2019
  1. Hugo W, Shi H, Sun L, et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 2015 ; 162 : 1271–1285. [CrossRef] [PubMed] [Google Scholar]
  2. Bertolotto C, Lesueur F, Giuliano S, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011 ; 480 : 94–98. [CrossRef] [PubMed] [Google Scholar]
  3. Bonet C, Luciani F, Ottavi JF, et al. Deciphering the role of oncogenic MITFE318K in senescence delay and melanoma progression. J Natl Cancer Inst 2017; 109 (8). [Google Scholar]
  4. Bertolotto C, Lesueur F, Bressac de Paillerets B. MIFT, une clé génétique du mélanome et du carcinome rénal. Med Sci Paris 2012; 28 : 258–61. [Google Scholar]
  5. Cheli Y, Giuliano S, Botton T, et al. Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene 2011 ; 30 : 2307–2318. [Google Scholar]
  6. Cheli Y, Giuliano S, Fenouille N, et al. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene 2012 ; 31 : 2461–2470. [Google Scholar]
  7. Ohanna M, Giuliano S, Bonet C, et al. Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev 2011 ; 25 : 1245–1261. [CrossRef] [PubMed] [Google Scholar]
  8. Ratnikov BI, Scott DA, Osterman AL, et al. Metabolic rewiring in melanoma. Oncogene 2017 ; 36 : 147–157. [Google Scholar]
  9. Falletta P, Sanchez-Del-Campo L, Chauhan J, et al. Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma. Genes Dev 2017 ; 31 : 18–33. [CrossRef] [PubMed] [Google Scholar]
  10. Canto C, Menzies KJ, Auwerx J. NAD (+) metabolism and the control of energy homeostasis: A balancing act between mitochondria and the nucleus. Cell metabolism 2015 ; 22 : 31–53. [CrossRef] [PubMed] [Google Scholar]
  11. Audrito V, Manago A, La Vecchia S, et al. Nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic target in BRAF-mutated metastatic melanoma. J Natl Cancer Inst 2018 ; 110 : [Google Scholar]
  12. Ohanna M, Cerezo M, Nottet N, et al. Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype. Genes Dev 2018 ; 32 : 448–461. [CrossRef] [PubMed] [Google Scholar]
  13. Audrito V, Manago A, Zamporlini F, et al. Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma. Oncotarget 2018 ; 9 : 18997–19005. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.